Professor, Medicine, University of Minnesota Medical School
Internal Medicine
Cohn practices Internal Medicine. He graduated from Weill Cornell Medical College of Cornell University. Weill Cornell Medical College of Cornell University is ranked 18 in research and 49 in primary care medicine He received awards:"CMS Meaningful Use Stage 1 Certification", "Distinguished Scientist Award", "Life Achievement Award", "Mastership", "Alumni Association Award of Distinction", "Lifetime Achievement Award", "Clinical Scholar Award", "Distinguished Scientist Award (Clinical Domain)", "International Scientist of the year", "International Prize for Scientific Research: Lifetime Achievement in Heart Failure", "Ignacio Chavez Medal of Honor", "Lifetime Achievement in Research", "Academic Health Center Academy for Excellence in Health Research", "James B. Herrick Award", "Novartis Award in Hypertension Research", "Kaufman Center for Heart Failure Award", "Discovery Award", "Scientific Councils' Distinguished Achievement Award", "The Best Doctors in America: Central Region", "Award for Outstanding Contribution in Research and Development", "The 250 Top Doctors in Twin City Area", "The 400 Best Doctors in America", "Listed in Best Doctors in America", "Sir Thomas Lauder Brunton Award", "William S. Harvey Award", "Distinguished Service Award", "Arthur S. Flemming Award", "Annual Award", "Alpha Omega Alpha", "Elected Member", "Scholar", "Fellow (FACC)" and "Who's Who in Medicine and Healthcare". Cohn is a published physician. He published 100 publications, including: 'Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials.'
Publications
- Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials.
- G-Protein Beta-3 Subunit Genotype Predicts Enhanced Benefit of Fixed-Dose Isosorbide Dinitrate and Hydralazine: Results of A-HeFT (African American Heart Failure Trial).
- Effect of Fixed-Dose Combination of Isosorbide Dinitrate and Hydralazine on All Hospitalizations and on 30-day Readmission Rates in Patients with Heart Failure: Result...
- The Autonomic Nervous System and Heart Failure.
- Prognostic Value of Soluble ST2 in the Valsartan Heart Failure Trial.
- Heart failure in 2013: Continue what we are doing to treat HF, but do it better.
- The Message is Clear: Prevent as Well as Treat Acute Myocardial Infarction.
- Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document.
- Preventing heart failure: a critique of strategies.
- Identifying the Risk and Preventing the Consequences of Cardiovascular Disease.
- Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT.
- Effect of carvedilol, lisinopril and their combination on vascular and cardiac health in patients with borderline blood pressure: the DETECT Study.
- ACP Journal Club. Fractional flow reserve-guided PCI reduced urgent revascularization at 7 months in coronary artery disease.
- Underuse of cardiovascular preventive pharmacotherapy in patients presenting with ST-elevation myocardial infarction.
- Stage B, a precursor of heart failure, part II.
- Stage B, a Pre-cursor of Heart Failure.
- Serial Measurement of Cardiac Troponin T Using a Highly Sensitive Assay in Patients with Chronic Heart Failure: Data from Two Large Randomized Clinical Trials.
- Direct-acting vasodilators.
- Is activation of the renin-angiotensin system hazardous to your health?
- Atrial fibrillation and mortality in African American patients with heart failure: Results from the African American Heart Failure Trial (A-HeFT).
- Vascular and cardiac functional and structural screening to identify risk of future morbid events: preliminary observations.
- ACP journal club. Review: Antihypertensive treatment prevents cardiovascular events and mortality in cardiovascular disease without hypertension.
- Pharmacotherapy: Inhibiting LV remodeling-the need for a targeted approach.
- Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarena...
- Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial.
- Heart failure is preventable.
- Cardiovascular pharmacotherapy 2010: foreword.
- Role of the renin-angiotensin system in cardiovascular disease.
- Detecting the patient at risk of heart failure.
- President's Page: ISCP's educational goals.
- Relationship of quality of life scores with baseline characteristics and outcomes in the African-American heart failure trial.
- Definition and classification of hypertension: an update.
- Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moder...
- The president's page: target response or target dose.
- Conflicts of interest: to eliminate them or manage them.
- Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trial.
- Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia.
- Exploring the potential synergistic action of spironolactone on nitric oxide-enhancing therapy: insights from the African-American Heart Failure Trial.
- Time to foster a rational approach to preventing cardiovascular morbid events.
- Monitoring adherence to guidelines.
- Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial.
- Identifying early cardiovascular disease to target candidates for treatment.
- Establishing a new option for target-organ protection: rationale for ARB plus ACE inhibitor combination therapy.
- Reducing cardiovascular risk by blockade of the renin-angiotensin-aldosterone system.
- Beneficial effects of valsartan in asymptomatic individuals with vascular or cardiac abnormalities: the DETECTIV Pilot Study.
- Myocardial structural effects of aldosterone receptor antagonism in heart failure.
- Arterial stiffness as a risk factor for coronary atherosclerosis.
- Efficacy and safety in clinical trials.
- Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial.
- Role of nitric oxide deficiency and its detection as a risk factor in pre-hypertension.
- Is it the blood pressure or the blood vessel?
- In memorium louis tobian.
- What is the role of angiotensin-receptor blockade in cardiovascular protection?
- Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A-HeFT Trial.
- Efficacy and safety in clinical trials in cardiovascular disease.
- Monitoring vascular health beyond blood pressure.
- Measuring endothelial function.
- Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology.
- B-type natriuretic peptide and artery stiffness.
- Prognosis and mechanism of death in treated heart failure: data from the placebo arm of Val-HeFT.
- Relationships between clinical assessments and patients' perceptions of the effects of heart failure on their quality of life.
- B-type natriuretic peptide level had reduced specificity for diagnosing heart failure in dyspnea with atrial fibrillation in the emergency department.
- Arterial stiffness, vascular disease, and risk of cardiovascular events.
- The use of race and ethnicity in medicine: lessons from the African-American Heart Failure Trial.
- Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT.
- Arterial elasticity as part of a comprehensive assessment of cardiovascular risk and drug treatment.
- Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart Failure Trial.
- A-HeFT: old dog, new endothelial tricks.
- Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT).
- New therapeutic strategies for heart failure: left ventricular remodeling as a target.
- Task force 2: Investigator participation in clinical research.
- Determinants of radial artery pulse wave analysis in asymptomatic individuals.
- Surrogate markers for cardiovascular disease: functional markers.
- Introduction to surrogate markers.
- Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data.
- The James B. Herrick Award Lecture. 2003. Clinical research: whose agenda is it?
- Blood pressure and the therapy of advanced heart failure.
- Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy.
- Clinical experience with perindopril in African-American hypertensive patients: a large United States community trial.
- Definition, classification, and staging of the adult cardiomyopathies: a proposal for revision.
- Antihypertensive utility of perindopril in a large, general practice-based clinical trial.
- Remodeling as an end-point in heart failure therapy.
- Beta-blockers for heart failure.
- Screening for early detection of cardiovascular disease in asymptomatic individuals.
- Ventricular remodeling in heart failure: a credible surrogate endpoint.
- Nitric oxide's role in heart failure: pathophysiology and treatment. Introduction.
- Effect of Valsartan on hospitalization: results from Val-HeFT.
- Review: concomitant aspirin use does not reduce the effectiveness of ACE inhibitors.
- Reduced small artery but not large artery elasticity is an independent risk marker for cardiovascular events.
- Endothelial dysfunction and the metabolic syndrome.
- Symposium reporter 2003. New therapeutic options in the management of hypertension to heart failure. Orlando, Florida, USA, March 6, 2003.
- Global structural ventricular remodeling: summation.
- Sympathetic nervous system in heart failure.
- Lessons learned from the valsartan- heart failure trial (Val-HeFT): angiotensin receptor blockers in heart failure.
- Prognostic application of arterial stiffness: task forces.
- Contemporary treatment of heart failure: is there adequate evidence to support a unique strategy for African-Americans? Pro position.
- Nuggets, pearls, and vignettes of master heart failure clinicians. Part 4--treatment.
- Techniques for studying arterial elastic properties.
- Hypertension therapeutic research: a plea for change in the new millennium.
Schools
Weill Cornell Medical College
Beth Israel Hospital
VA Hospital
Georgetown University
Doctors Specialties
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Distinguished Scientist Award
- Life Achievement Award
- Mastership
- Alumni Association Award of Distinction
- Lifetime Achievement Award
- Clinical Scholar Award
- Distinguished Scientist Award (Clinical Domain)
- International Scientist of the year
- International Prize for Scientific Research: Lifetime Achievement in Heart Failure
- Ignacio Chavez Medal of Honor
- Lifetime Achievement in Research
- Academic Health Center Academy for Excellence in Health Research
- James B. Herrick Award
- Novartis Award in Hypertension Research
- Kaufman Center for Heart Failure Award
- Discovery Award
- Scientific Councils' Distinguished Achievement Award
- The Best Doctors in America: Central Region
- Award for Outstanding Contribution in Research and Development
- The 250 Top Doctors in Twin City Area
- The 400 Best Doctors in America
- Listed in Best Doctors in America
- Sir Thomas Lauder Brunton Award
- William S. Harvey Award
- Distinguished Service Award
- Arthur S. Flemming Award
- Annual Award
- Alpha Omega Alpha
- Elected Member
- Scholar
- Fellow (FACC)
- Who's Who in Medicine and Healthcare
Education
-
Georgetown University Hospital
-
Beth Israel Deaconess Medical Center
-
Weill Cornell Medical College of Cornell University
Hospital
-
University of Minnesota Medical Center, Fairview
Helpful Reviews
Give
Anonymous Review
Similar Doctors
Doctor Directory | TOS | twitter | FB | Angel | blog
This Doctor is OpenDoctor Recommended.